摘要
[目的]研究BRAF在前列腺癌组织中表达及其临床意义。[方法]采用免疫组织化学技术检测74例前列腺癌、39例前列腺增生组织的BRAF蛋白表达,并对其与临床病理因素的关系进行相关性分析。[结果]前列腺癌与增生组织BRAF蛋白表达阳性率分别为64.86%与10.26%,二者差异有显著性意义(P<0.05)。前列腺癌组中,中高分化病例与低分化病例BRAF蛋白表达阳性率分别为43.48%与74.51%,二者差异有显著性意义(P<0.05);(A+B)期(无浸润转移)病例与(C+D)期(有浸润转移)病例BRAF蛋白表达阳性率分别为42.50%与91.18%,二者差异有显著性意义(P<0.05);≤60岁病例与>60岁病例BRAF蛋白表达阳性率分别为59.52%与71.88%,二者差异无显著性意义(P>0.05)。[结论]在前列腺癌组织BRAF蛋白表达明显增高,且与组织的分化、肿瘤临床分期及发生发展相关,检测其表达可能会有助与诊断和预后判断。
[Objective] To investigate the clinicopathological relations of BRAF expression in prostate cancer.[Methods] Immunohistochemistry was used to detect the expression of BRAF in 74 cases of prostate carcinoma,and 39 cases of benign prostate hyperplasia（BPH）.[Results] The positive rate of BRAF in the prostate carcinoma（64.86%） was significantly higher than that of BPH（10.26%）（P0.05）.The expression of BRAF was correlated with grade and stage of prostate cancer（P0.05）,but not to age of onset（P0.05）.[Conclusion] The abnormal expression of BRAF may play a role in the tumorigenesis and progression of prostate carcinoma,detection of which may be helpful to diagnose the cancer and predict its prognosis.
出处
《大连医科大学学报》
CAS
2010年第6期652-654,共3页
Journal of Dalian Medical University
关键词
前列腺癌
免疫组化
BRAF
prostate carcinoma
immunohistochemistry
BRAF
